Key result
3-Phenoxybenzoic acid increases cardiac Nav1.5 late sodium current and slows cardiomyocyte depolarization rate.
Why the study?
Epidemiological data link urinary 3-phenoxybenzoic acid (3-PBA) to increased cardiometabolic risk and coronary heart disease, but the underlying electrophysiological mechanisms of its direct potential cardiotoxicity and effects on heart excitability had not been investigated.
Does the pyrethroid metabolite 3-phenoxybenzoic acid (3-PBA) impair human cardiac Nav1.5 channel function and action potential depolarization in human and rodent cellular and ex vivo cardiac models?
Does the pyrethroid metabolite 3-phenoxybenzoic acid (3-PBA) impair human cardiac Nav1.5 channel function and action potential depolarization in human and rodent cellular and ex vivo cardiac models?
This study provides the first direct evidence that the ubiquitous pyrethroid insecticide metabolite 3-PBA is electrophysiologically active, impairing cardiac Nav1.5 inactivation and action potential depolarization in human and rodent cardiomyocytes.
3-PBA augments late sodium current and slows depolarization in cardiac models; leaves open any contribution to human arrhythmogenesis from pyrethroid exposure.
Pyrethroid insecticides (PYRs) are widely used worldwide, and their primary metabolite, 3-phenoxybenzoic acid (3-PBA), serves as a near-ubiquitous biomarker of human exposure to PYRs. While epidemiological data consistently link urinary 3-PBA to increased cardiometabolic risk and coronary heart disease, the underlying electrophysiological mechanisms of its direct potential cardiotoxicity remain unexplored. Parent PYRs are known to exert cardiotoxic effects by enhancing the late sodium current (I Na-L ) and inducing arrhythmia, but the direct effect of 3-PBA on heart excitability has not been previously investigated. This study demonstrates that 3-PBA interacts with human cardiac Na v 1.5 expressed in Human Embryonic Kidney (HEK293) cells, and significantly increases I Na-L in a concentration-dependent manner with an EC 50 of 51.3 ± 5.1 µM. The metabolite does not alter the voltage dependence of activation and inactivation, but it significantly delays the recovery from inactivation of the peak sodium current. In human induced pluripotent stem cell–derived cardiomyocytes (CM-hiPSCs) and adult rat ventricular myocytes, 3-PBA reduced maximal depolarization rate (dV/dt), indicating impaired depolarization dynamics and reduced peak sodium current. At the organ level, acute exposure in isolated rat hearts did not significantly alter standard ECG parameters. Collectively, these findings suggest that 3-PBA is not electrophysiologically inert but directly modulates cardiac sodium channel function, although at supraphysiological concentration. This provides new evidence of the biological activity of 3-PBA and suggests that its cardiotoxic potential may become clinically relevant under conditions of high dose and chronic exposure or in susceptible populations. Graphical Abstract Pyrethroid metabolite 3-phenoxybenzoic acid (3-PBA) increased the late sodium current in Na v 1.5 expressed in Human embryonic kidney 293 and delayed the recovery from inactivation. Also, 3-PBA in relevant concentration to human toxicology reduced the maximal rate of action potential depolarization (dV/dt) in rat ventricular cardiomyocytes and human induced pluripotent stem cell-derived cardiomyocyte. In the ECG of ex vivo heart preparation 3-PBA 1 μM caused non-effect. This provides evidence of the biological activity of 3-PBA and suggests that its cardiotoxic potential may become clinically relevant under conditions of high dose and chronic exposure or in susceptible populations. Created by Servier Medical Art ( https://smart.servier.com ), licensed under CC BY 4.0 ativecommons.org/licenses/by/4.0/). Gemini 3.1 Pro was used to refine the layout and visual presentation of the graphical abstract. The authors reviewed, verified, and approved all generated content.
No takes yet. Share an insight, caveat, or question.
Conceição et al. (2026) studied Pyrethroid metabolite cardiotoxicity and cardiac sodium channel (Nav1.5) dysfunction. 3-phenoxybenzoic acid (3-PBA) vs. Control (0.1% DMSO vehicle) was evaluated on Late sodium current (INa-L) in HEK293 cells expressing human cardiac Nav1.5 (EC50 51.3 ± 5.1 µM (2.3-fold to 5.5-fold increase), p=<0.05). 3-Phenoxybenzoic acid (3-PBA) increased human cardiac Nav1.5 late sodium current in a concentration-dependent manner (EC50 51.3 ± 5.1 µM, p<0.05) and reduced cardiomyocyte depolarization rate (dV/dt).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: